|
Colorectal Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
The major aim of this study was to evaluate the performance of anti-BRAF V600E (VE1) antibody in colorectal tumors with and without KRAS mutation.
|
29127628 |
2019 |
|
Colorectal Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation testing of colorectal tumors demonstrating aberrant MLH1 protein expression by IHC was the most common secondary tumor test, with 53% of laboratories performing the test; 15% of laboratories also applied the BRAF V600E test to endometrial tumors with aberrant MLH1 expression despite no evidence for its utility.
|
30294856 |
2018 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
|
25989278 |
2015 |
|
Colorectal Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
Our results support the use of VE1 IHC for identification of colorectal neoplasms harboring the BRAF V600E mutation.
|
25517872 |
2015 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
|
24163374 |
2014 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.
|
24594804 |
2014 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
|
23549875 |
2013 |
|
Colorectal Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
To verify the technical characteristics of the microarray system for the correct identification of the KRAS mutational status at the two hotspot codons 12 and 13 and of the BRAF(V600E) mutation in colorectal tumor, we selected 75 samples previously characterized by conventional and CO-amplification at Lower Denaturation temperature-PCR (COLD-PCR) followed by High Resolution Melting analysis and direct sequencing.
|
23536897 |
2013 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
|
23251002 |
2013 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.
|
23845441 |
2013 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.
|
23812671 |
2013 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Our findings indicated that proteasome inhibition might represent a valuable targeting strategy in BRAF V600E-mutant colorectal tumors.
|
24107445 |
2013 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.
|
23325582 |
2013 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
|
22180495 |
2012 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
|
22448344 |
2012 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
|
22608338 |
2012 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
|
22281684 |
2012 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
BRAF as a target for cancer therapy.
|
21426297 |
2011 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
|
21163703 |
2011 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis.
|
20857202 |
2011 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.
|
20350999 |
2010 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
20619739 |
2010 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
|
20413299 |
2010 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
|
21129611 |
2010 |